Dysregulation of the NRG1/ERBB pathway causes a developmental disorder with gastrointestinal dysmotility in humans
Authors:
- Thuy-Linh LeTLThuy-Linh Le
- Louise GalmicheLGLouise Galmiche
- Jonathan LevyJLJonathan Levy
- Pim SuwannaratPSPim Suwannarat
- Debby M.E.I. HellebrekersDHDebby M.E.I. Hellebrekers
- Khomgrit MorarachKMKhomgrit Morarach
- Franck BoismoreauFBFranck Boismoreau
- Tom E.J. TheunissenTTTom E.J. Theunissen
- Mathilde LefebvreMLMathilde Lefebvre
- Anna PeletAPAnna Pelet
- Jelena MartinovicJMJelena Martinovic
- Antoinette GelotAGAntoinette Gelot
- 15 March 2021
- journal article
- research article
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 131 (6)
Abstract
Hirschsprung disease (HSCR) is the most frequent developmental anomaly of the enteric nervous system, with an incidence of 1 in 5000 live births. Chronic intestinal pseudo-obstruction (CIPO) is less frequent and classified as neurogenic or myogenic. Isolated HSCR has an oligogenic inheritance with RET as the major disease-causing gene, while CIPO is genetically heterogeneous, caused by mutations in smooth muscle–specific genes. Here, we describe a series of patients with developmental disorders including gastrointestinal dysmotility, and investigate the underlying molecular bases. Trio-exome sequencing led to the identification of biallelic variants in ERBB3 and ERBB2 in 8 individuals variably associating HSCR, CIPO, peripheral neuropathy, and arthrogryposis. Thorough gut histology revealed aganglionosis, hypoganglionosis, and intestinal smooth muscle abnormalities. The cell type–specific ErbB3 and ErbB2 function was further analyzed in mouse single-cell RNA sequencing data and in a conditional ErbB3-deficient mouse model, revealing a primary role for ERBB3 in enteric progenitors. The consequences of the identified variants were evaluated using quantitative real-time PCR (RT-qPCR) on patient-derived fibroblasts or immunoblot assays on Neuro-2a cells overexpressing WT or mutant proteins, revealing either decreased expression or altered phosphorylation of the mutant receptors. Our results demonstrate that dysregulation of ERBB3 or ERBB2 leads to a broad spectrum of developmental anomalies, including intestinal dysmotility.Keywords
Funding Information
- Agence Nationale de la Recherche under the “Investissements d’avenir” program (ANR-10-IAHU-01)
- MSD-Avenir (DEVO–DECODE project)
- Association Francophone de la Maladie de Hirschsprung (-)
- Association « Rires et tapage chez les Hirschsprung » (-)
- Fondation pour la Recherche Médicale (FDT201904008113)
This publication has 68 references indexed in Scilit:
- Structural Analysis of the Mechanism of Inhibition and Allosteric Activation of the Kinase Domain of HER2 ProteinJournal of Biological Chemistry, 2011
- Bone morphogenetic proteins regulate enteric gliogenesis by modulating ErbB3 signalingDevelopmental Biology, 2011
- Differential Contributions of Rare and Common, Coding and Noncoding Ret Mutations to Multifactorial Hirschsprung Disease LiabilityThe American Journal of Human Genetics, 2010
- Structural analysis of the catalytically inactive kinase domain of the human EGF receptor 3Proceedings of the National Academy of Sciences, 2009
- Novel anticancer targets: revisiting ERBB2 and discovering ERBB3Nature Reviews Cancer, 2009
- Genome-wide association study identifies NRG1 as a susceptibility locus for Hirschsprung's diseaseProceedings of the National Academy of Sciences, 2009
- EGF–ERBB signalling: towards the systems levelNature Reviews Molecular Cell Biology, 2006
- Phosphotyrosine interactome of the ErbB‐receptor kinase familyMolecular Systems Biology, 2005
- ERBB receptors and cancer: the complexity of targeted inhibitorsNature Reviews Cancer, 2005
- A common sex-dependent mutation in a RET enhancer underlies Hirschsprung disease riskNature, 2005